Propoxyphene

CHEMBL1213351 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
339.5 g/mol
LogP
4.2
Phase
4

Propoxyphene is a synthetic opioid analgesic of the diphenylheptane class that acts primarily as a mu-opioid receptor agonist to produce analgesia, sedation, and euphoria, with potency approximately half that of codeine. It was used for mild to moderate pain management but was withdrawn globally due to its cardiac toxicity, particularly QT prolongation and potentially fatal arrhythmias even at therapeutic doses.

分子量

339.5000 g/mol

LogP

4.20

TPSA

29.50 Ų

リピンスキーの五則

適合

治療領域

作用機序

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C

InChI

InChI=1S/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m1/s1

Molecular Formula

C22H29NO2

HBD / HBA

- / 3

回転可能結合数

9

重原子数

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Propoxyphene is a synthetic opioid analgesic of the diphenylheptane class that acts primarily as a mu-opioid receptor agonist to produce analgesia, sedation, and euphoria, with potency approximately half that of codeine. It was used for mild to moderate pain management but was withdrawn globally due to its cardiac toxicity, particularly QT prolongation and potentially fatal arrhythmias even at therapeutic doses.

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Yes, Propoxyphene is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1213351. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 10100. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.